Page last updated: 2024-09-05

erlotinib hydrochloride and Laryngeal Neoplasms

erlotinib hydrochloride has been researched along with Laryngeal Neoplasms in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Francis, DO; Garrett, CG; McWhorter, A; Misono, S; Somerville, J	1
Batra, RK; Dubinett, SM; Limsukon, A; Soo Hoo, GW; Susanto, I	1
Domínguez-Fernández, I; Eguren, C; García-Díez, A; Santiago-Sánchez-Mateos, DI	1
Araújo, CM; Bezerra, M; Dias, FL; Federico, MH; Ferreira, CG; Fontão, K; Herchenhorn, D; Knust, RE; Martins, RG; Small, I; Viegas, CM	1

Trials

1 trial(s) available for erlotinib hydrochloride and Laryngeal Neoplasms

Article	Year
Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. International journal of radiation oncology, biology, physics, 2010, Nov-01, Volume: 78, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Confidence Intervals; Drug Administration Schedule; Drug Eruptions; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Oropharyngeal Neoplasms; Quinazolines; Radiotherapy Dosage; Salvage Therapy; Survival Rate	2010

Article

Year

Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.

International journal of radiation oncology, biology, physics, 2010, Nov-01, Volume: 78, Issue:3

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Confidence Intervals; Drug Administration Schedule; Drug Eruptions; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Oropharyngeal Neoplasms; Quinazolines; Radiotherapy Dosage; Salvage Therapy; Survival Rate

2010

Other Studies

3 other study(ies) available for erlotinib hydrochloride and Laryngeal Neoplasms

Article	Year
Resolution of vocal fold leukoplakia during erlotinib treatment for lung cancer. Ear, nose, & throat journal, 2016, Volume: 95, Issue:2 Topics: Aged; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Incidental Findings; Laryngeal Neoplasms; Leukoplakia; Lung Neoplasms; Male; Vocal Cords	2016
Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy. Chest, 2009, Volume: 136, Issue:3 Topics: Biopsy; Bronchoscopy; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Papilloma; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides	2009
[Erlotinib-induced acneiform rash not affecting previously irradiated skin]. Actas dermo-sifiliograficas, 2010, Volume: 101, Issue:2 Topics: Acneiform Eruptions; Antineoplastic Agents; Arm; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Facial Dermatoses; Humans; Laryngeal Neoplasms; Laryngectomy; Male; Middle Aged; Neck Dissection; Neoplasm Proteins; Organ Specificity; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Skin; Thorax	2010